妓院一钑片免看黄大片,亚洲av无码成人精品国产,亚洲AV综合色区无码专区桃色,免费A级毛片在线播放不收费

加拿大Allon Therapeutics Inc.
Allon Therapeutics Inc. (溫哥華，Vancouver)是著重在神經系統保護的科技公司，也就是The Neuro Protection Company? 。公司宣布已擴大進行中臨床測試范圍，將增加阿爾滋海默癥病人列入受測對象，并研究AL–108在這些病人身上的藥物動力學。Allon宣布2008年1月10日已在一項額外的臨床測試中啟動用藥，評估在正常健康個體中，施用AL–108 及 AL–208這兩個藥物對腦脊液(cerebrospinal fluid，CSF)及血漿藥物動力學(plasma pharmacokinetics，PK)產生的影響。公司執行長兼總裁Gordon McCauley先生指出，增加阿爾滋海默癥病人為受測對象，反應出公司正在強化現行臨床計劃，同時也是要確保公司在進入阿爾滋海默癥病人臨床第IIB期藥物有效性測試設計之前，己取得有力的證據數據。公司預定在2008年本季取得公司藥物在阿爾滋海默癥前身的健忘型輕度知能障礙(amnestic mild cognitive impairment， aMCI)病人的臨床第IIA期有效性測試資料之后，會在2008年內正式啟動阿爾滋海默癥病人臨床第IIB期測試。 公司執行長兼總裁McCauley先生補充指出，在PK研究中增加阿爾滋海默癥病人，將可以看出阿爾滋海默癥病人在用藥安全方面和健康成人是否有差別，同時也讓公司了解當進入到阿爾滋海默癥病人臨床第IIB期測試時，該期待那些結果。在這項PK研究中增加阿爾滋海默癥病人，也讓公司了解到一些在阿爾滋海默癥病人腦脊液出現的生物標識分子，進一步可以去觀察在這項人類疾病病理動作的一些分子修飾機制。

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon’s drug davunetide intranasal (AL-108) has demonstrated human efficacy in amnestic mild cognitive impairment, a precursor to Alzheimer’s disease. Allon has Phase II human efficacy programs pursuing large underserved markets: Alzheimer’s disease, frontotemporal dementia, and schizophrenia-related cognitive impairment. The Company is listed on the Toronto Stock Exchange under the trading symbol “NPC” (Neuro Protection CompanyTM) and based in Vancouver.

Allon's milestones for 2009 include:

Execute a partnership agreement with a major pharmaceutical company
Initiate a Phase II study in frontotemporal dementia
Commence a Phase IIb study in AD with a partner
Initiate a Phase II PET study in AD patients
Announce top-line results from the Phase II study in schizophrenia-related cognitive impairment
Alzheimer’s disease
The first drug to treat Alzheimer’s disease came out in 1993. Since then, drugs have been developed that offer some symptomatic relief, but have no impact on the disease process or its progression. (Source: Paul Aisen, MD. Director, the Alzheimer’s Disease Cooperative Study, U.S. National Institutes of Health. Professor, School of Medicine, Department of Neurosciences, University of California, San Diego.)

“The combination of the symptomatic impact shown in this clinical trial and Allon’s pre-clinical data showing an impact on plaques and tangles, the classic hallmarks of Alzheimer’s disease, highlights the potential of davunetide intranasal (AL-108) as a disease-modifying therapy”.

(Donald Schmechel, MD. Adjunct Professor of Medicine (Geriatics), Duke University Medical Center, Durham, North Carolina. Medical Director, The Falls Neurological and Memory Center, Caldwell Memorial Hospital, Lenoir, North Carolina.)

Human efficacy

Allon released positive results from a Phase IIa clinical trial that showed two daily 15 mg doses of davunetide intranasal (AL-108) over 12 weeks of treatment resulted in statistically significant, dose-dependent and durable improvements on key endpoints that measure short-term recall and working memory — two types of memory that are clinically relevant in Alzheimer’s disease – in patients diagnosed with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s disease.

Reduces “tangles”, increases memory

In July 2008, Allon’s scientific presentations at the International Conference on Alzheimer’s Disease and Related Disorders (ICAD 2008) in Chicago demonstrated that the Phase IIa aMCI clinical trial data support the results of several studies in animals that show davunetide intranasal (AL-108) reduced the classic Alzheimer’s “tangles” pathology and also increased memory function.